Analysis of a public breast cancer gene expression database indicated that reduced TRIM29 expression was associated with reduced relapse-free survival (RFS), increased tumor size, grade, and metastatic characteristics. Taken together, our results suggest that TRIM29 acts as a tumor suppressor in breast cancer through its ability to inhibit TWIST1 and suppress EMT.
INTRODUCTION
Currently, more than 70 members of the Tripartite Motif (TRIM) family (also referred to as RBCC) have been identified in humans and are typically classified due to the presence of a tripartite set of motifs including a RING domain, one or two B-box motifs and a coiled-coil region (1) . In addition to these motifs, several family members contain additional protein-protein interaction domains such as BROMO, PHD, MATH and SPRY domains (2) . The presence of multiple protein-protein interaction motifs is thought to provide TRIM family members with significant plasticity in interaction with various binding partners (3, 4) . TRIM proteins have been implicated in a spectrum of biological roles such as control of innate immune response, cancer, and development (for review see 2, 5).
Examination of TRIM29 (aka ATDC) expression in various tumor types has found that increased expression of TRIM29 is associated with more aggressive forms of disease including bladder (6) , colorectal (7), gastric (8) , lung (9, 10) , and pancreatic cancer (11) . Further, several studies have shown an association between elevated TRIM29 expression and reduced patient survival (6, 8) . In support of an oncogenic role for TRIM29, investigators found that overexpression of TRIM29 in pancreatic cancer lines promoted cell growth in
qRT-PCR Analysis
Total RNA was isolated from cultured cell lines or frozen breast tissues using TRI Reagent (Ambion). cDNA synthesis was conducted with the High Capacity RNA-to-cDNA Kit, qPCR conducted with Power SYBR Green master mix (Life Technologies) using an Applied Biosystems StepOnePlus theromocycler. Fold changes in relative transcript abundance were calculated with the 2 (-ΔΔCt) method (16) using GAPDH as the internal standard. Primers used for qRT-PCR are listed in Supplementary Table SI. Results shown are the mean of at least three independent experimental replicates. 
Breast Tumor and Normal Tissue Specimens

DNA Methylation Analysis
Genomic DNA was isolated from cell lines and frozen tissues with TRI Reagent. DNA was bisulfite modified using the EZ DNA methylation kit (ZYMO) as previously outlined (17) .
Quantitative DNA methylation analysis was conducted by pyrosequencing as previously described (18) . A 247 bp segment of the TRIM29 gene was amplified from bisulfite converted DNA using primers outlined in Supplementary Table SI and pyrosequencing conducted using the indicated sequencing primer. Bisulfite genomic sequencing was conducted using standard protocols (19) .
Pyrosequencing results shown are the mean of at least three independent experimental replicates.
RNA Interference
For RNAi-mediated knockdown of TRIM29, shRNA lentiviral vectors (TRCN0000016351 (#1) or TRCN0000016352 (#2)) were obtained from Open Biosystems. Lentivirus encoding shRNA or empty pLKO.1 vectors were packaged in HEK-293T cells (ATCC) as previously outlined (15) . Selection with 2 µg/ml puromycin was conducted for approximately 1-3 weeks prior to analysis of the resultant polyclonal cell populations.
ON-TARGET plus human TWIST1 siRNA SMART pool and siRNA control were purchased from Thermo Scientific. Unless otherwise specified, cells were transfected with 200 nM siRNA using Lipofectamine 2000 (Life Technology) and 48 hr post transfection cells were harvested and analyzed as indicated.
Recombinant Protein Expression
For transient protein expression, cells were transfected with pcDNA3.1-HA-ATDC (13) (gift of Dr. E. Seto, Moffitt Cancer Center), pcDNA 3.1-HA-TWIST1, or Myc-Twist1-pCS2 or (gift of Dr. R. Maestro, CRO Aviano National Cancer Institute, Italy) using TurboFect Transfection Reagent (Thermo Scientific).
Where indicated, the control vectors (pcDNA3.1 or Myc-GFP-pCS3) were transfected in parallel. 48 hr post-transfection, cells were harvested and indicated experimentation conducted. For stable expression of recombinant FLAG-tagged TRIM29, retrovirus was packaged in HEK-293T by co-transfecting with either pMX-puro-FLAG-TRIM29/ATDC or control pMX-puro (20) , along with psPAX2 and pCL-ECO (Addgene).
In Vitro Cell Invasion Assay
Cell invasion assay was measured via modified Boyden chamber assay as described previously (21) . 24 hr after seeding into the top well, the bottom well was fixed and stained with Diff-Quik, invading cells photographed in 10 randomly selected fields and counted.
Cell Proliferation Assay
Cell proliferation was measured using CellTiter Blue Reagent (Promega, Madison, WI) as directed by the manufacturer. Briefly, cells were seeded in 12 wells plates, and 24 and 48 hr later were washed twice with PBS and re-fed with complete growth medium containing 10% (v/v) CellTiter Blue Reagent. Cells were incubated at 37 o C for an additional for 90 min and subsequently 100 μl of medium was removed and fluorescence measured (560nm excitation / 590nm emission wavelength) using a BMG Labtech fluorometer. Cell proliferation at 48 hr was calculated relative to the fluorescence value recorded at 24 hr. Graphed is the result of at least three independent assays. from human genomic DNA using primers outlined in Supplementary Table SI. The resultant amplicon was digested with NheI and XhoI at primer encoded restriction sites, and subsequently subcloned into pGL3-Basic (Promega). A recombinant clone (pTRIM29-Luc) was confirmed by automated Sanger sequencing. Transcriptional activity was measured in transiently transfected cells using the Dual-Luciferase reporter assay system (Promega) as previously outlined (22) . Results of transcriptional reporter assays shown represent the mean of at least three independent experiments.
Chromatin Immunoprecipitation (ChIP)
ChIP with anti-HA antibody was performed as previously outlined (15) .
Briefly, cells were harvested, proteins were briefly cross-linked with 1% formaldehyde (RT, 10 min), washed and resuspended in ice-cold TEG buffer (10 mM Tris, 1 mM EDTA, 0.5 mM EGTA, pH 8.0). Cells were sonicated on ice for 8 X 30s, debris removed by centrifugation, and soluble chromatin was immunoprecipitated with anti-HA (Thermo) or control mouse IgG (Sigma). DNA was isolated from pelleted immunocomplexes and qPCR carried out using primers outlined in Supplementary Table SI. Shown is the mean from at least three independent ChIP assays for each indicated cell line.
RESULTS
The TRIM29 gene is a target for epigenetic silencing in cultured breast cancer cell lines
We observed that TRIM29 was only detected in the tumor lines SK-BR-3, MDA-MB-468, and non-tumorigenic mammary epithelium-derived MCF-10A and immortalized human mammary epithelium cells (HMEC) by immunoblotting ( Fig   1A) , consistent with a previous study (23) . Further, when relative TRIM29 mRNA was quantified by qRT-PCR, transcript was only detectable in these four cell lines (Fig 1B) .
We inspected the architecture of the human TRIM29 gene locus ( Fig 1C and Supplementary Fig S1) . The TRIM29 gene is located at 11q23.3, is comprised of 9 exons, and spans ~44.5 kb (Supplementary Fig 1A) .
Superimposed upon exon 1 is a 664 bp GC-rich feature classified as a "CpG island" (Supplementary Fig 1B) (24) . Aberrant dense cytosine methylation within CpG islands is associated with transcriptional repression and epigenetic gene silencing (25).
Given the low/absent expression of TRIM29 in many cultured breast cancer lines and TRIM29 gene architecture, we tested for epigenetic silencing by culturing MDA-MB-231 and MCF7 cells on the global DNA demethylating drug 5-aza-deoxyCytidine (5-azadC). qRT-PCR analysis of RNA harvested 3 and 5 days after drug addition indicated a multi-fold rise in TRIM29 transcript in both lines but not in 5-azadC treated MDA-MB-468 cells (Fig 1D) . Coordinately, 5-azadC treatment resulted in a notable rise in TRIM29 protein expression in MDA-MB-231 and MCF7 (Fig 1E) . A pyrosequencing assay was developed to measure DNA methylation within a 35 bp region (containing 5 CpG dinucleotides) of the TRIM29 CpG island (see Supplementary Fig S1) . MCF-10A cells contained extremely low levels of CpG methylation (mean=0.4%) while human genomic DNA methylated in vitro displayed near complete methylation (mean=98.8%) within the TRIM29 gene ( Fig   1F) . Very low levels of TRIM29 methylation were measured in SK-BR-3 and MDA-MB-468 cells (mean=4.2% for both lines) (Fig 1G) . In contrast, untreated MDA-MB-231 and MCF7 cells displayed elevated CpG methylation (mean=74.2% and 76.2%, respectively) ( Fig 1H) . Consistent with gene reexpression, 5 days of 5-azadC produced a measureable decrease in TRIM29 methylation (mean=22.6% and 27.4%, respectively). Pyrosequencing analysis of the remaining breast tumor lines initially assayed for TRIM29 expression indicated similarly high levels of TRIM29 gene methylation (Supplementary Fig   S2A) .
Bisulfite genomic sequencing (BGS) was also conducted on several breast cancer cell lines to examine DNA methylation density within the TRIM29 gene.
Representative data obtained from MDA-MB-231 cells, but not SK-BR-3, indicates this line contains a pattern of dense CpG methylation within single DNA templates of the TRIM29 gene (Fig 1I) . This finding is consistent with obtained pyrosequencing results and further supports that aberrant CpG methylation occurs within the TRIM29 gene. indicated relatively low levels of CpG methylation (mean=12.6% and 20.6%, respectively) (Fig 2A) . These levels of gene methylation are consistent with values obtained when 9 additional normal human breast samples were assayed for TRIM29 CpG methylation (mean = 18.0%, SE=8.0%) (Fig 2B, Supplementary   Fig S2B) . Primary breast tumor specimens Br-T16 and Br-T18 contained a high methylation (mean=61.6% and 81.0%, respectively), and lower levels of CpG methylation were measured in tumor sample Br-T8 (mean=27.2%) (Fig 2A) , thus aberrant TRIM29 methylation occurs in primary breast tumors.
To further examine the relationship between TRIM29 mRNA abundance and TRIM29 gene methylation we measured TRIM29 mRNA levels in 11 normal and 30 primary breast tumor specimens (Fig 2C and Supplementary Fig S2C) .
qRT-PCR analysis revealed that 12 of the tumor samples displayed TRIM29 mRNA abundance that was equal to or greater than the geometric mean (+/-1.96 SE) measured in normal breast tissues. This analysis also indicated that some breast tumors, like other tumor types (6) (7) (8) (9) (10) (11) , display overexpression of the TRIM29 gene relative to normal mammary tissue. We currently do not understand the molecular basis of high TRIM29 expression in these tumors, however, the 11q23 locus is a common site of chromosomal instability in breast cancer (26). Mean TRIM29 methylation within this group of tumors was not Fig S2B) .
qRT-PCR analysis also revealed that the majority (n=18) of breast tumors displayed a significant reduction in TRIM29 mRNA relative to normal breast tissue ( Fig 2C and Supplementary Fig S2C) . Similarly, pyrosequencing indicated a significant elevation in mean TRIM29 gene methylation compared to normal tissues ( Fig 2B and Supplementary Fig S2B) . When relative TRIM29 mRNA and TRIM29 gene methylation in the breast tumors with low TRIM29 mRNA levels were analyzed on a scatterplot, we observed a significant (P<0.001) inverse correlation between TRIM29 mRNA levels and gene methylation (Fig 2D) . From these studies we conclude that the TRIM29 gene is commonly hypermethylated in cultured breast cancer cells and primary breast tumors, and is a novel target for epigenetic silencing.
Knockdown of TRIM29 results in increased breast cancer cell motility and invasiveness
The recent work of Liu et al (14) showed that reduced expression of TRIM29 in MCF-10A cells altered cellular behavior. To extend these findings we cultures of SK-BR-3 and MDA-MB-468 cells within 2 weeks of TRIM29 knockdown using two independent shRNA vectors ( Fig 3B) . Specifically, both lines acquired a spindle-like morphology commonly associated with motile cells (27) . In contrast, cultures of MCF-10A or HMEC displayed a less dramatic change in morphology following TRIM29 knockdown (data not shown).
48 hr after wounding monolayer cultures, we observed increased cell migration into the wound in each TRIM29 knockdown line compared to control lines ( Fig 3C) . Invasion assays on cells with and without TRIM29 knockdown were conducted using a modified Boyden chamber assay ( Fig 3D) and we measured statistically significant increases in invasive activity in each line following TRIM29 knockdown (Fig 3E) . Finally, a proliferation assay indicated that TRIM29 knockdown significantly increased cell growth rates relative to controls ( Fig 3F) . These experiments reveal that TRIM29 knockdown in cultured breast tumor and non-tumorigenic cell lines increases cell motility, proliferation, and invasiveness.
TWIST1 is upregulated and gene expression patterns altered following TRIM29 knockdown
Increased invasive behavior is often linked to alterations in gene expression patterns resulting in downregulation of epithelial and upregulation of mesenchymal genes (27). SK-BR-3 do not express E-cadherin (28), a prominent epithelial marker, but we observed a measureable decrease in both E-cadherin protein ( Fig 4A) and transcript abundance (Fig 4B) in MDA-MB-468 cells following TRIM29 knockdown. In contrast, no detectable alteration in E-cadherin protein was observed in MCF-10A (Fig 4A) , but a ~2-fold decrease in CDH1 EpCAM and increased N-cadherin expression, (Supplementary Fig S3A, B) , indicating that these effects are specific to TRIM29 knockdown.
TWIST1 and TRIM29 exhibit a reciprocal relationship
To better understand the relationship between TRIM29 and TWIST1 we transiently expressed recombinant HA-tagged TRIM29 in SK-BR-3 and MDA-MB-468 cells and observed endogenous TWIST1 levels decreased in both lines (Fig 5A) . We also observed expression of recombinant Myc-tagged Twist1 decreased endogenous TRIM29 abundance (Fig 5B) . qRT-PCR indicated that TRIM29 expression resulted in a significant drop in TWIST1 transcript and, conversely, that expression of recombinant Twist1 decreased TRIM29 mRNA ( Fig 5C) .
We next transfected SK-BR-3 or MDA-MB-468 cells with TWIST1-specific or control siRNA and observed that TWIST1-specific siRNA resulted in knockdown of TWIST1 and increase in TRIM29 protein (Fig 5D) . Similarly, we measured a dose-dependent increase in TRIM29 transcript in SK-BR-3 and MDA-MB-468 cells after TWIST1 knockdown with siRNA ( Fig 5E,F, respectively) .
Since N-cadherin is a direct transcriptional target of TWIST1 (30), we also analyzed SK-BR-3 cells for expression of this gene following TWIST1 knockdown. The results indicate TWIST1 knockdown resulted in a significant dose-dependent decrease in N-cadherin mRNA abundance in SK-BR-3 ( Fig 5E) .
Similar results were obtained when control and TRIM29 shRNA knockdown SK-BR-3 cells were transfected with TWIST1 siRNA (Supplementary Fig S4) , supporting the conclusion that TWIST1 is driving N-cadherin expression following TRIM29 knockdown. We obtained a luciferase reporter plasmid (pGL3-Twist-Luc) containing a segment of the human TWIST1 promoter (31). We observed when cotransfected with recombinant TRIM29 into HEK-293T cells that luciferase activity was decreased compared to cells co-transfected with reporter and control (pcDNA3.1) vector (Fig 5G) , suggesting that TRIM29 antagonizes transcription of the TWIST1 gene. TWIST1 reporter assays conducted in SK-BR-3 and MDA-MB-468 cells indicated a significant increase in reporter activity following TRIM29 knockdown ( Fig 5H) . We conclude that TRIM29 and TWIST1 antagonize the activity and/or expression of each other, implying the presence of a novel negative feedback loop.
TWIST1 inhibits TRIM29 promoter activity.
Inspection of the 5' flank of the human TRIM29 gene revealed the presence of 10 canonical E-box sequences (5'-CANNTG-3') within a cluster upstream of the transcriptional start site of the TRIM29 gene (nt# -349 to -747, Fig 6A) . We amplified a 1,100 bp fragment of the TRIM29 proximal promoter and cloned it into a luciferase-linked reporter plasmid (pGL3-Basic). When this construct (pTRIM29-Luc) was transfected into HEK-293T cells we measured a multi-fold increase in luciferase activity compared to controls (Fig 6B) , indicating this segment possesses promoter activity. When pTRIM29-Luc reporter was cotransfected into HEK-293T along with recombinant TWIST1, we observed repressed luciferase activity (Fig 6B) . We also measured decreased TRIM29 reporter activity in both SK-BR-3 and MDA-MB-468 TRIM29 knockdown lines cells compared to controls (Fig 6C) , indicating that reduced TRIM29 protein containing multiple E-boxes (see Fig 6A) . To conduct these experiments, we transiently expressed HA-tagged human TWIST1 in SK-BR-3 and MDA-MB-468 cells with and without TRIM29 knockdown (Fig 6D) . qPCR measured significantly increased relative enrichment of the targeted locus in chromatin precipitated using anti-HA compared to chromatin precipitated with non-specific mouse IgG (Fig 6E) , indicating interaction of recombinant TWIST1 with the targeted region of the TRIM29 gene. Further, increases in relative enrichment of HA-TWIST1 interaction with TRIM29 were measured in chromatin harvested from TRIM29 knockdown SK-BR-3 and MDA-MB-468 cells (Fig 6E) , suggesting that reduced TRIM29 protein was allowing increased association of TWIST1 with the TRIM29 gene.
We also stably expressed recombinant FLAG-tagged human TRIM29 in two breast tumor lines (BT-549 and MDA-MB-231) that have silenced endogenous TRIM29 expression, and HA-TWIST1 was expressed for the purpose of conducting ChIP (Fig 6D) . ChIP assays indicated that expression of recombinant TRIM29 protein resulted in a significant reduction in relative enrichment of the TRIM29 promoter segment compared to cells not expressing recombinant TRIM29 (Fig 6F) We used breast cancer data within the KM-Plotter database (32) to investigate the association of TRIM29 expression with breast cancer survival.
This analysis indicated that low TRIM29 expression was significantly (P<0.0001) associated with reduced relapse-free survival (RFS) compared to patients with higher TRIM29 expression (Fig 7A) . Of note, we found no significant association between TRIM29 expression and overall survival (OS) in this set of breast cancer patients.
Comparison of breast tumors ≤2cm with tumors >2cm indicated TRIM29 expression is significantly lower in the larger tumors (Fig 7B) . We also observed that higher grade (Grades 2 and 3) tumors displayed significantly lower TRIM29 expression compared to Grade 1 tumors (Fig 7C) . Of note, we found no significant difference when TRIM29 expression was compared between Grade 2 and Grade 3 tumors (P=0.43, Mann-Whitney test). Lower TRIM29 expression was also associated with tumors positive for lymph node spread compared to node-negative tumors (Fig 7D) . Independent of either patient age at diagnosis, lymph node status, tumor size or grade, or ER expression, low TRIM29 expression was found to be a significant predictive factor for reduced RFS in breast cancer patients when multivariate survival analysis using a Cox model was applied to this data set ( Supplementary Fig S5A-E, Supplementary Table 2 ).
In sum, low TRIM29 expression is associated with reduced relapse-free survival, cells also slowed growth rates and reduced anchorage-independent growth (14) and we have observed similar effects in BT-549 and MDA-MB-231 cells (data not shown). Conversely, knockdown of TRIM29 in MCF-10A cells promoted anchorage-independent growth, increased cell motility and invasiveness, and disrupted 3D acinar formation in vitro (14) . We have confirmed these findings using a broader panel of breast tumor and mammary epithelium-derived cell lines, and extended these studies by determining that knockdown of TRIM29 in breast cancer cells altered gene expression patterns in a manner consistent with increased cell motility and invasiveness. In sum, available evidence firmly supports the conclusion that TRIM29 functions in a growth/invasion suppressive capacity in mammary epithelial cells.
We observed that breast cancer patients with tumors exhibiting reduced TRIM29 expression have reduced relapse-free survival (RFS). Further, low TRIM29 expression is associated with more aggressive tumor features. Liu et al (14) observed reduced survival in young women with ER+ tumors, but reported no difference in older women with ER+ breast cancer. Analysis of the database used in our study revealed low TRIM29 expression was significantly associated with poorer RFS regardless of patient age at diagnosis (Supplementary Fig S5A) .
While clearly in need of further analysis and data refinement, these facts suggest that TRIM29 expression may be useful as a prognostic breast cancer biomarker.
Our study of breast cancer cells with TRIM29 knockdown indicated that concomitant with reduced TRIM29 expression was a coordinate increase in TWIST1, a bHLH transcription factor that, like other bHLH proteins (i.e., SNAIL, SLUG, ZEB1 and ZEB2), functions in an oncogenic role in breast cancer (35). Specifically, transcription factors of this subgroup promote the epithelial to mesenchymal transition (EMT) during cancer progression. EMT is an embryonic program that governs cell motility and, accordingly, TWIST1 is critical for closure of the neural tube during embryogenesis (36). In the context of cancer, activation of EMT promotes otherwise non-motile and polarized epithelial cells to lose polarity and cell-cell contact, and invade adjacent stroma (29). For this reason, increased TWIST1 activity is associated with metastatic activity (35). As our study demonstrates TRIM29 suppresses TWIST1 expression and activity, we conclude that this activity is at least one mechanism by which TRIM29 functions to suppress breast cancer development.
We observed that TRIM29 knockdown results in upregulation of TWIST1 and, conversely, that expression of TRIM29 drives down TWIST1 levels in cultured breast cancer cells. These findings suggest that TRIM29 has an inhibitory role on the transcription of the TWIST1 gene. Further, expression of recombinant TRIM29 resulted in reduced association of TWIST1 with the TRIM29 gene as judged by ChIP. These findings imply that TRIM29 interferes with the function of the TWIST1 protein. At present we are unsure of the mechanism(s) that underlie these observations. As TRIM29 antagonizes p53 function by sequestering this transcription factor in the cytoplasm (13), it is tempting to speculate that TRIM29 could be functioning in a parallel role to sequester factor(s) that promote TWIST1 transcription. Alternatively, while TRIM29 has been characterized as a cytoplasmic protein (3) and has not been reported to interact with chromatin, it contains two B-box Zn-finger motifs and Ai et al T13 T14 T15 T16 T17 T18 T19 T20 T21 T22 T23 T24 T25 T26 T27 T28 T29 
